Clinical TrialsSearch results
Number of results: 230
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- The Effect of Peripheral Ischemia-Reperfusion Stimulation on Improving Glucose Tolerance in Type 2 Diabetes Patients Receiving aNtidiabetic Drugs or Basal Insulin Replacement Therapy
- type 2 diabetes mellitus
- Kurabayashi Atsushi
- 2026-02-10
Recruiting
- ARTCEREB Refill test Intrathecal of Study Effectiveness
- cerebrospinal fluid hypovolemia
- Eiichi Nakai
- 2026-01-16
Recruiting
- STRESS-FREE Trial
- Nocturia
- Shimizu Nobutaka
- 2025-11-18
Recruiting
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
- Chronic Spontaneous Urticaria
- Kawai Norisuke
- 2025-11-14
Recruiting
- An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001
- Moderate to Severe Plaque Psoriasis
- Kojima Yuri
- 2025-07-29
Other
- Open label, single arm study of aficamten in Japanese oHCM
- symptomatic obstructive hypertrophic cardiomyopathy
- Myoishi Masafumi
- 2025-06-19
Recruiting
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF EVO756 IN ADULTS WITH MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA
- Chronic Spontaneous Urticaria
- Nishiura Tomoyuki
- 2025-05-27
Recruiting
- A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti-Interleukin [IL]-33 monoclonal antibody [mAb]) in participants with inadequately-controlled chronic rhinosinusitis with nasal polyps
- Chronic rhinosinusitis with nasal polyps
- Obara Kentaro
- 2025-05-12
Recruiting
- A Phase 3b, Randomised, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)
- Intermediate Risk Non-muscle invasive bladder cancer
- Sandstroem Per
- 2025-04-28
Recruiting
- [M24-727]A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis
- Atopic Dermatitis
- Otani Tetsuya
- 2025-03-17